TherapeuticsMD (TXMD) Share-based Compensation (2010 - 2026)
TherapeuticsMD (TXMD) posted Share-based Compensation of $2000.0 for Q1 2026, down 96.08% on a QoQ basis from $51000.0 in Q4 2025, and down 91.3% year-over-year from $23000.0 in Q1 2025.
TherapeuticsMD (TXMD) Share-based Compensation (2010 - 2026) Analysis & Trends
TherapeuticsMD's Share-based Compensation history runs 17 years deep, the most recent figure standing at $2000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 91.3% year-over-year to $2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54000.0 (down 69.32% YoY) and the FY2025 annual result came in at $75000.0, down 71.59% from the prior year.
- Share-based Compensation was $2000.0 for Q1 2026 at TherapeuticsMD, down from $51000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $12.2 million in Q2 2022 and bottomed at $1000.0 in Q2 2025.
- A 5-year average of $1.4 million and a median of $113500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 5250.88% — and 2025, when it tumbled 98.96%.
- TherapeuticsMD's Share-based Compensation stood at $1.1 million in 2022, then sank by 89.45% to $116000.0 in 2023, then tumbled by 79.31% to $24000.0 in 2024, then surged by 112.5% to $51000.0 in 2025, then sank by 96.08% to $2000.0 in 2026.
- Business Quant data shows TXMD's Share-based Compensation at $2000.0 in Q1 2026, $51000.0 in Q4 2025, and $1000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,000.00 |
| Mar 31, 2026 | 2,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Dec 31, 2025 | 51,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Dec 31, 2024 | 24,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 116,000.00 |
| Dec 31, 2023 | 116,000.00 |
| Sep 30, 2023 | 233,000.00 |
| Sep 30, 2023 | 233,000.00 |